Maxim Group analyst Jason McCarthy maintained a Hold rating on Omeros (OMER – Research Report) yesterday. The company’s shares closed yesterday at $7.13.
According to TipRanks, McCarthy is an analyst with an average return of -37.6% and a 16.55% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Atossa Therapeutics, and Capricor Therapeutics.
Currently, the analyst consensus on Omeros is a Hold with an average price target of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $16.57 and a one-year low of $1.86. Currently, Omeros has an average volume of 1.48M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Read More on OMER:
